New investigations on retatruded, a dual agonist for glucagon-like peptide-1 and GIP, suggest encouraging outcomes in managing excess body fat and type 2 diabetic condition. Early evidence from clinical assessments show substantial decreases in body mass and bettered glucose regulation. Further exploration is directed on long-term safety and eff… Read More